The global anti-obesity medical devices market was valued at USD 2.40 billion in 2025. It is estimated at USD 2.51 billion in 2026 and is projected to reach USD 4.41 billion by 2036, growing at a CAGR of 5.8% over the 2026-2036 forecast period. This report examines the market in depth, covering the obesity treatment gap, the effect of GLP-1 medications on procedure demand, device technologies, clinical evidence, regulation and reimbursement, the device pipeline, pricing, the value chain, and competition.
The study covers medical devices that treat obesity or help patients reach and hold a lower body weight, whether through surgery or less invasive procedures. In scope are staplers, reloads, energy, access, and suturing devices, and robotic instruments used in bariatric surgery; systems for endoscopic sleeve gastroplasty (ESG), duodenal resurfacing, and duodenal liners; balloons placed by endoscope or swallowed as a capsule; adjustable bands; nerve stimulation devices; and oral or ingestible products that limit intake or increase fullness. Medicines, and consumer slimming products not regulated as medical devices, fall outside the scope. The value chain links device makers and specialist developers with hospitals, surgery centers, obesity clinics, surgeons and gastroenterologists, payers, and professional societies.
According to the World Health Organization, 890 million adults were living with obesity in 2022, which points to a very large clinical need. The American Society for Metabolic and Bariatric Surgery (ASMBS) counted 270,089 U.S. bariatric operations in 2023, and according to the society, less than 1% of eligible people undergo surgery each year. GLP-1 medications have nevertheless cut into device demand, and procedures at accredited American centers slipped to just over 177,000 in 2024, about 23% under the 2022 peak, according to American College of Surgeons data presented at the ASMBS meeting in May 2026.
The main restraint is the use of GLP-1 medications in place of procedures, which has hit less invasive devices hardest; ASMBS estimates show U.S. intragastric balloon procedures falling from 4,358 in 2022 to 1,461 in 2023, and Intuitive Surgical has reported repeated quarterly declines in U.S. bariatric cases on its robots. Specialist developers are financially fragile: Allurion Technologies reported quarterly revenue that halved year on year in the third quarter of 2025, AspireAssist and vagal blocking therapy were withdrawn, and Gelesis went bankrupt in 2023. Most payers do not routinely reimburse balloons or ESG, earlier FDA safety letters on fluid-filled balloons still weigh on adoption, and developers must prove lasting value against both drugs and surgery, combine devices with medication, and plan around uncertain procedure volumes.
Weight maintenance after patients stop GLP-1 therapy is the most important opportunity, as a JAMA Network Open study of more than 125,000 U.S. patients reported that 64.8% of those without diabetes discontinued GLP-1 treatment within a year, and the STEP 1 extension showed that most of the weight lost returns after stopping. Device-drug combinations and rising surgical volumes in emerging markets, where branded GLP-1 drugs remain costly, add further opportunity. Key trends include the move from surgery as a stand-alone option to a multi-modal care pathway, the growth of endoscopic and swallowable devices, a surgical mix tilting toward bypass and revisions, and digital and muscle-preservation support in device programs.
Based on device type, the market is segmented into surgical devices (stapling devices, energy devices, access & suturing devices, and robotic instruments & accessories), endoscopic devices (endoscopic suturing & plication systems, duodenal mucosal resurfacing systems, and endoscopic liners), intragastric balloons (endoscopically placed and swallowable balloons), gastric bands, neuromodulation devices, and ingestible & oral devices. Surgical devices are expected to hold the largest share in 2026, as sleeve gastrectomy, gastric bypass, and revisional operations continue at scale and each case uses staplers, reloads, energy devices, and often robotic instruments; bypass and revisions, with more staple lines and anastomoses, also raise device value per case. Endoscopic devices are expected to grow at the highest CAGR, helped by the July 2022 FDA indication for ESG, randomized evidence such as the MERIT trial, new duodenal therapies, and patient interest in avoiding surgery. Boston Scientific's 2023 purchase of Apollo Endosurgery placed ESG and balloon products inside a large endoscopy portfolio.
Based on approach, the market is segmented into surgical, endoscopic, and swallowable & non-invasive. The surgical approach is expected to lead in 2026, reflecting broad insurance coverage, a long clinical record, and the lasting efficacy of bariatric operations. The swallowable & non-invasive segment is expected to grow at the highest CAGR, driven by the February 2026 FDA approval of the Allurion Gastric Balloon System, swallowed as a capsule without endoscopy or sedation, and the chance to treat patients in clinics rather than endoscopy suites.
Based on treatment intent, the market is segmented into primary weight loss, weight maintenance after pharmacotherapy, revisional treatment, and combination therapy. Primary weight loss is expected to lead in 2026, because first-time bariatric procedures still make up most device use and most approved indications target initial weight reduction. Weight maintenance after pharmacotherapy is expected to grow at the highest CAGR, as many patients stop GLP-1 drugs within a year, regain much of the lost weight, and need a durable follow-on option; Fractyl Health's REMAIN-1 study of Revita is the key test of this use. Revisional and combination use are also gaining attention as surgeons revise earlier sleeves and developers pair devices with lower drug doses.
Based on BMI category, the market is segmented into BMI 27.5 to 34.9, BMI 35 to 39.9, and BMI 40 and above. The BMI 40 and above segment is expected to lead in 2026, since bariatric surgery is concentrated among patients with severe obesity who meet long-standing eligibility rules and gain the most health benefit. The BMI 27.5 to 34.9 segment is expected to grow at the highest CAGR, supported by guidelines that lower the surgical threshold for Asian patients to a BMI of 27.5 and by the focus of balloons, ESG, and other less invasive devices on moderate obesity.
Based on end user, the market is segmented into hospitals, ambulatory surgery centers, and specialty obesity & gastroenterology clinics. Hospitals are expected to hold the largest share in 2026, as accredited bariatric programs, surgical robots, and complex revision cases sit mainly in hospitals. Specialty obesity & gastroenterology clinics are expected to grow at the highest CAGR, as endoscopic and swallowable devices move treatment out of the operating room and as clinics build programs that combine devices with medication-based care.
North America is expected to remain the largest regional market in 2026, as the U.S. performs more bariatric procedures than any other country, hosts leading suppliers such as Johnson & Johnson MedTech, Intuitive Surgical, and Boston Scientific, and often approves new less invasive devices first, including the swallowable Allurion balloon in February 2026. In Canada, provincial systems fund surgery, but waiting lists limit access. Europe holds a significant share and has often been the launch market for new obesity devices, with public systems in the U.K., France, Germany, Italy, Spain, and the Nordic countries funding surgery while many do not pay for GLP-1 drugs for weight loss.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to rising obesity and diabetes, lower BMI thresholds for Asian patients that greatly widen the eligible pool, and growing surgical and endoscopic capacity. China has more bariatric centers and local stapler makers each year, India's private hospitals are building programs, and branded GLP-1 drugs remain costly relative to incomes. In Latin America, Brazil and Mexico lead, with Brazil covering surgery through public and private plans and Mexico serving medical tourists. The Middle East & Africa is expected to record strong growth, led by Gulf states such as Kuwait, Saudi Arabia, Qatar, and the UAE with very high obesity rates, while Türkiye is a hub for bariatric medical tourism.
Large medtech firms dominate surgical stapling, energy, and robotics, while balloons, endoscopic and duodenal therapies, and other less invasive devices come from many smaller developers with thin finances. Competition turns on efficacy and durability, safety, ease of use, reimbursement, evidence, and fit with drug-based care. Leaders are adapting to GLP-1 drugs by focusing on revisional surgery, robotic and powered stapling, endoscopic platforms, drug combinations, and maintenance indications. Notable moves include Boston Scientific's 2023 acquisition of Apollo Endosurgery, the 2026 FDA approval of Allurion's swallowable balloon alongside the company's shift toward combining it with low-dose GLP-1 therapy, and Fractyl Health's pivotal program for maintenance after tirzepatide.
Key companies profiled in the report include Medtronic plc (Ireland), Johnson & Johnson MedTech (Ethicon) (U.S.), Intuitive Surgical, Inc. (U.S.), Teleflex Incorporated (U.S.), Applied Medical Resources Corporation (U.S.), CONMED Corporation (U.S.), Boston Scientific Corporation (U.S.), Olympus Corporation (Japan), Cook Medical LLC (U.S.), Endo Tools Therapeutics S.A. (Belgium), Allurion Technologies, Inc. (U.S.), Fractyl Health, Inc. (U.S.), ReShape Lifesciences Inc. (U.S.), GI Dynamics, Inc. (U.S.), and Spatz Medical (U.S.).
The study covers medical devices that treat obesity or help patients reach and hold a lower body weight, whether through surgery or less invasive procedures. In scope are staplers, reloads, energy, access, and suturing devices, and robotic instruments used in bariatric surgery; systems for endoscopic sleeve gastroplasty (ESG), duodenal resurfacing, and duodenal liners; balloons placed by endoscope or swallowed as a capsule; adjustable bands; nerve stimulation devices; and oral or ingestible products that limit intake or increase fullness. Medicines, and consumer slimming products not regulated as medical devices, fall outside the scope. The value chain links device makers and specialist developers with hospitals, surgery centers, obesity clinics, surgeons and gastroenterologists, payers, and professional societies.
According to the World Health Organization, 890 million adults were living with obesity in 2022, which points to a very large clinical need. The American Society for Metabolic and Bariatric Surgery (ASMBS) counted 270,089 U.S. bariatric operations in 2023, and according to the society, less than 1% of eligible people undergo surgery each year. GLP-1 medications have nevertheless cut into device demand, and procedures at accredited American centers slipped to just over 177,000 in 2024, about 23% under the 2022 peak, according to American College of Surgeons data presented at the ASMBS meeting in May 2026.
Market Dynamics
Growth rests on a large population with obesity that remains mostly untreated, on the durable weight loss that surgery and other device-based treatments deliver, and on new approvals that widen the choice of less invasive options. According to a records analysis presented at the ASMBS 2026 meeting, 90% to 95% of U.S. patients with severe obesity went without any obesity therapy from 2018 to 2025. The 2022 ASMBS and IFSO guidelines lowered surgical eligibility to a BMI of 35 regardless of comorbidities, and to 30 for people with metabolic disease. On efficacy, a 51,085-patient study from NYU Langone Health reported at the ASMBS 2025 meeting showed 24% total weight loss at two years after sleeve gastrectomy or gastric bypass, against 4.7% for patients prescribed GLP-1 drugs for at least six months. Because devices do not rely on long-term drug adherence, they suit patients who cannot tolerate, afford, or stay on medication.The main restraint is the use of GLP-1 medications in place of procedures, which has hit less invasive devices hardest; ASMBS estimates show U.S. intragastric balloon procedures falling from 4,358 in 2022 to 1,461 in 2023, and Intuitive Surgical has reported repeated quarterly declines in U.S. bariatric cases on its robots. Specialist developers are financially fragile: Allurion Technologies reported quarterly revenue that halved year on year in the third quarter of 2025, AspireAssist and vagal blocking therapy were withdrawn, and Gelesis went bankrupt in 2023. Most payers do not routinely reimburse balloons or ESG, earlier FDA safety letters on fluid-filled balloons still weigh on adoption, and developers must prove lasting value against both drugs and surgery, combine devices with medication, and plan around uncertain procedure volumes.
Weight maintenance after patients stop GLP-1 therapy is the most important opportunity, as a JAMA Network Open study of more than 125,000 U.S. patients reported that 64.8% of those without diabetes discontinued GLP-1 treatment within a year, and the STEP 1 extension showed that most of the weight lost returns after stopping. Device-drug combinations and rising surgical volumes in emerging markets, where branded GLP-1 drugs remain costly, add further opportunity. Key trends include the move from surgery as a stand-alone option to a multi-modal care pathway, the growth of endoscopic and swallowable devices, a surgical mix tilting toward bypass and revisions, and digital and muscle-preservation support in device programs.
Segment Analysis
The report analyzes the market by device type, approach, treatment intent, BMI category, end user, and geography, helping stakeholders see where demand and device value are moving.Based on device type, the market is segmented into surgical devices (stapling devices, energy devices, access & suturing devices, and robotic instruments & accessories), endoscopic devices (endoscopic suturing & plication systems, duodenal mucosal resurfacing systems, and endoscopic liners), intragastric balloons (endoscopically placed and swallowable balloons), gastric bands, neuromodulation devices, and ingestible & oral devices. Surgical devices are expected to hold the largest share in 2026, as sleeve gastrectomy, gastric bypass, and revisional operations continue at scale and each case uses staplers, reloads, energy devices, and often robotic instruments; bypass and revisions, with more staple lines and anastomoses, also raise device value per case. Endoscopic devices are expected to grow at the highest CAGR, helped by the July 2022 FDA indication for ESG, randomized evidence such as the MERIT trial, new duodenal therapies, and patient interest in avoiding surgery. Boston Scientific's 2023 purchase of Apollo Endosurgery placed ESG and balloon products inside a large endoscopy portfolio.
Based on approach, the market is segmented into surgical, endoscopic, and swallowable & non-invasive. The surgical approach is expected to lead in 2026, reflecting broad insurance coverage, a long clinical record, and the lasting efficacy of bariatric operations. The swallowable & non-invasive segment is expected to grow at the highest CAGR, driven by the February 2026 FDA approval of the Allurion Gastric Balloon System, swallowed as a capsule without endoscopy or sedation, and the chance to treat patients in clinics rather than endoscopy suites.
Based on treatment intent, the market is segmented into primary weight loss, weight maintenance after pharmacotherapy, revisional treatment, and combination therapy. Primary weight loss is expected to lead in 2026, because first-time bariatric procedures still make up most device use and most approved indications target initial weight reduction. Weight maintenance after pharmacotherapy is expected to grow at the highest CAGR, as many patients stop GLP-1 drugs within a year, regain much of the lost weight, and need a durable follow-on option; Fractyl Health's REMAIN-1 study of Revita is the key test of this use. Revisional and combination use are also gaining attention as surgeons revise earlier sleeves and developers pair devices with lower drug doses.
Based on BMI category, the market is segmented into BMI 27.5 to 34.9, BMI 35 to 39.9, and BMI 40 and above. The BMI 40 and above segment is expected to lead in 2026, since bariatric surgery is concentrated among patients with severe obesity who meet long-standing eligibility rules and gain the most health benefit. The BMI 27.5 to 34.9 segment is expected to grow at the highest CAGR, supported by guidelines that lower the surgical threshold for Asian patients to a BMI of 27.5 and by the focus of balloons, ESG, and other less invasive devices on moderate obesity.
Based on end user, the market is segmented into hospitals, ambulatory surgery centers, and specialty obesity & gastroenterology clinics. Hospitals are expected to hold the largest share in 2026, as accredited bariatric programs, surgical robots, and complex revision cases sit mainly in hospitals. Specialty obesity & gastroenterology clinics are expected to grow at the highest CAGR, as endoscopic and swallowable devices move treatment out of the operating room and as clinics build programs that combine devices with medication-based care.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with analysis of 23 countries, the Nordic countries, Southeast Asia, UAE & Qatar, and four rest-of-region groups. The regional analysis considers obesity prevalence, procedure volumes, guideline thresholds, reimbursement for surgical and non-surgical treatment, access to GLP-1 medications, and regulatory approval timing.North America is expected to remain the largest regional market in 2026, as the U.S. performs more bariatric procedures than any other country, hosts leading suppliers such as Johnson & Johnson MedTech, Intuitive Surgical, and Boston Scientific, and often approves new less invasive devices first, including the swallowable Allurion balloon in February 2026. In Canada, provincial systems fund surgery, but waiting lists limit access. Europe holds a significant share and has often been the launch market for new obesity devices, with public systems in the U.K., France, Germany, Italy, Spain, and the Nordic countries funding surgery while many do not pay for GLP-1 drugs for weight loss.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to rising obesity and diabetes, lower BMI thresholds for Asian patients that greatly widen the eligible pool, and growing surgical and endoscopic capacity. China has more bariatric centers and local stapler makers each year, India's private hospitals are building programs, and branded GLP-1 drugs remain costly relative to incomes. In Latin America, Brazil and Mexico lead, with Brazil covering surgery through public and private plans and Mexico serving medical tourists. The Middle East & Africa is expected to record strong growth, led by Gulf states such as Kuwait, Saudi Arabia, Qatar, and the UAE with very high obesity rates, while Türkiye is a hub for bariatric medical tourism.
Competitive Landscape
The report reviews key growth strategies, competitive benchmarking, and the competitive dashboard, grouping companies into industry leaders, market differentiators, vanguards, and emerging companies, together with a 2025 market share/rank analysis. Company profiles cover business overview, financial overview, product portfolio, pipeline, strategic developments, and SWOT analysis, organized into surgical device and robotics leaders, endoscopy companies, and specialist obesity device developers.Large medtech firms dominate surgical stapling, energy, and robotics, while balloons, endoscopic and duodenal therapies, and other less invasive devices come from many smaller developers with thin finances. Competition turns on efficacy and durability, safety, ease of use, reimbursement, evidence, and fit with drug-based care. Leaders are adapting to GLP-1 drugs by focusing on revisional surgery, robotic and powered stapling, endoscopic platforms, drug combinations, and maintenance indications. Notable moves include Boston Scientific's 2023 acquisition of Apollo Endosurgery, the 2026 FDA approval of Allurion's swallowable balloon alongside the company's shift toward combining it with low-dose GLP-1 therapy, and Fractyl Health's pivotal program for maintenance after tirzepatide.
Key companies profiled in the report include Medtronic plc (Ireland), Johnson & Johnson MedTech (Ethicon) (U.S.), Intuitive Surgical, Inc. (U.S.), Teleflex Incorporated (U.S.), Applied Medical Resources Corporation (U.S.), CONMED Corporation (U.S.), Boston Scientific Corporation (U.S.), Olympus Corporation (Japan), Cook Medical LLC (U.S.), Endo Tools Therapeutics S.A. (Belgium), Allurion Technologies, Inc. (U.S.), Fractyl Health, Inc. (U.S.), ReShape Lifesciences Inc. (U.S.), GI Dynamics, Inc. (U.S.), and Spatz Medical (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global anti-obesity medical devices market through 2036.
- Explains how GLP-1 medications are changing procedure volumes, device mix, and the role of devices in obesity care.
- Assesses the impact of reimbursement gaps, safety scrutiny, and the financial fragility of specialist developers on adoption.
- Identifies high-growth opportunities across device type, approach, treatment intent, BMI category, end user, and region.
- Tracks emerging technologies such as swallowable balloons, endoscopic suturing, duodenal mucosal resurfacing, and drug-eluting devices.
- Benchmarks leading companies on product portfolios, pipelines, clinical evidence, strategic developments, and market position.
- Supports product planning, clinical strategy, market access, partnership, and investment decisions for device makers, providers, and investors.
Key Questions Answered
- How large is the global anti-obesity medical devices market today, and how will it grow through 2036?
- How have GLP-1 medications affected bariatric surgery, balloon, and endoscopic procedure volumes?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How large is the opportunity for devices that help patients maintain weight after stopping GLP-1 therapy?
- Which device type, approach, treatment intent, BMI category, and end user segments will grow the fastest?
- How do surgery, endoscopic procedures, swallowable balloons, and medications compare on clinical evidence?
- How do reimbursement and regulatory pathways differ for surgical and non-surgical obesity devices?
- Which regions and countries offer the most attractive opportunities for device suppliers?
- Who are the leading companies in the market, and what strategies are they using to adapt to the GLP-1 era?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Anti-Obesity Medical Devices Market, by Device Type
6. Anti-Obesity Medical Devices Market, by Approach
7. Anti-Obesity Medical Devices Market, by Treatment Intent
8. Anti-Obesity Medical Devices Market, by BMI Category
9. Anti-Obesity Medical Devices Market, by End User
10. Anti-Obesity Medical Devices Market, by Geography
11. Competitive Landscape
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Medtronic plc
- Johnson & Johnson MedTech
- Intuitive Surgical, Inc.
- Teleflex Incorporated
- Applied Medical Resources Corporation
- CONMED Corporation
- Boston Scientific Corporation
- Olympus Corporation
- Cook Medical LLC
- Endo Tools Therapeutics S.A.
- Allurion Technologies, Inc.
- Fractyl Health, Inc.
- ReShape Lifesciences Inc.
- GI Dynamics, Inc.
- Spatz Medical
